Conference Coverage

Intraventricular enzyme replacement slows CLN2 disease progression


 

REPORTING FROM AAN 2018

The results were published simultaneously in the New England Journal of Medicine.

BioMarin Pharmaceutical funded the work, along with grants from the German Federal Ministry of Education and Research, the European Union’s Horizon 2020 Research and Innovation Program, and the National Institute for Health Research. Several authors were BioMarin employees. Dr. de Los Reyes is a consultant and reported a grant from the company.

SOURCE: Schulz A et al. N Engl J Med. 2018 Apr 24. doi: 10.1056/NEJMoa1712649.

Pages

Recommended Reading

Abstracts Being Accepted for Cornelia de Lange Syndrome Foundation Symposium
MDedge Pediatrics
National Tissue Biobank Established for Coats Disease
MDedge Pediatrics
One-Day Conference Planned on Effects of Necrotizing Enterocolitis on Premature Infants and Families
MDedge Pediatrics
Progeria Research Foundation Scientific Workshop Planned
MDedge Pediatrics
RF-positive polyarticular JIA looks like adult RA
MDedge Pediatrics
‘Right to try’ bill passes House
MDedge Pediatrics
Chikungunya infection in children masquerades as SJS-TEN
MDedge Pediatrics
Longer poly-JIA inactivity not necessarily better before stopping anti-TNF therapy
MDedge Pediatrics
FDA approves burosumab to treat X-linked hypophosphatemia
MDedge Pediatrics
MDedge Daily News: Which nonopioids are ripe for abuse?
MDedge Pediatrics